Shares of Regulus Therapeutics ( RGLS, Financials) fell 24% to $0.89 as of 12:39 p.m. GMT-5 on Wednesday following the ...

Regulus Therapeutics Inc (RGLS) stock saw a decline, ending the day at $0.97 which represents a decrease of $-0.20 or -17.09% from the prior close of $1.17. The stock opened at $1.08 and touched a low ...

Insiders who bought US$82.3k worth of Regulus Therapeutics Inc.'s ( NASDAQ:RGLS ) stock at an average buy price ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regulus (RGLS – Research Report) and Roche ...

SAN DIEGO - Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company currently trading at $1.17 per share, today announced significant clinical and regulatory advancements in its ...

Regulus Therapeutics (NASDAQ:RGLS) shares tumbled 24% Wednesday after the biotech company reported results from a study analysis for its ADPKD program and issued a regulatory update. Regulus ...

Therapeutics announced positive clinical and regulatory updates from its ADPKD program. The update includes positive topline ...

Exciting February sky events include Venus at its brightest and closest to Earth, the moon occulting the Pleiades, and a parade of planets in the post-sunset sky.

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

In an indication that has proved difficult for biopharma to conquer, Regulus Therapeutics Inc. disclosed further positive data from its ongoing phase Ib study testing RGLS-8429 in autosomal dominant ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...